Anthony C. Wong, M.D., Ph.D.
Dr. Anthony Wong specializes in the treatment of thoracic and genitourinary malignancies. His research focuses on innovative applications of stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). He has a particular interest in treating lung cancer, prostate cancer and oligometastatic disease with linear accelerator-based and CyberKnife radiosurgery. He is the author of a currently accruing randomized clinical trial refining linear accelerator-based radiosurgery techniques, and his work has contributed to a growing body of literature defining the appropriate role of ablative local therapies in patients with oligometastases.
|2000-2004||Yale University||BS||Molecular Biophysics and Biochemistry|
|2005-2012||Albert Einstein College of Medicine||MD, PhD||Medicine, Biomedical Sciences|
|2012-2013||Memorial Sloan-Kettering Cancer Center||Internship||Transitional Year|
|2013-2017||University of Chicago||Resident||Radiation Oncology|
|2017- Present||University of California, San Francisco||Assistant Professor||Radiation Oncology|
Awards & Honors
|2012||Alpha Omega Alpha Honor Medical Society, Kappa New York Chapter|
|2015||American College of Radiation Oncology Resident Seed Grant|
|2015||Best of ASTRO abstract selection|
Das LC, Golden DW, Perevalova E, Wong AC, De Nardo K, Stepaniak C, Joyce DS, McCabe BP, Hasan Y, Chmura SJ, McCall A. A feasibility study of 2-mm bolus for postmastectomy radiation therapy. Pract Radiat Oncol. 2017;7(3):161-6. doi: 10.1016/j.prro.2016.10.015. PubMed PMID: 28089526.
Wong AC, Watson S, Pitroda S, Son CH, Das LC, Stack ME, Uppal, A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer 2016;122(14):2242-2250. PMID: 27206146.
Ranoa D, Parekh A, Pitroda S, Huang X, Darga T, Wong AC, Huang L, Andrade J, Staley J, Satoh T, Akira S, Weichselbaum RR, Khodarev NN. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 2016; 7(18):26496-26515. PMID: 27034163.
Wong AC, Stock S, Schrag D, Kahn KL, Salz T, Charlton ME, Rogers SO, Goodman, KA, Keating NL. Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer. J. Oncol. Pract. 2014;10(5):e360-7. PMID: 24986112.